m6A Target Gene Information

General Information of the m6A Target Gene (ID: M6ATAR00067)
Target Name hsa_circ_0008399
Synonyms
hsa-circ-0008399
    Click to Show/Hide
Gene Name hsa_circ_0008399
Full List of m6A Methylation Regulator of This Target Gene and Corresponding Disease/Drug Response(s)
hsa_circ_0008399 can be regulated by the following regulator(s), and cause disease/drug response(s). You can browse detail information of regulator(s) or disease/drug response(s).
Browse Regulator
Browse Disease
Browse Drug
Methyltransferase-like 14 (METTL14) [WRITER]
 Regulator Info 
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary Circ0008399 bound WTAP to promote formation of the WTAP/METTL3/METTL14 m6A methyltransferase complex, reduce cisplatin sensitivity in bladder cancer, implicating the potential therapeutic value of targeting this axis.
Target Regulation Up regulation
Responsed Disease Bladder cancer ICD-11: 2C94
 Disease Info 
Responsed Drug Cisplatin Approved
 Drug Info 
Pathway Response Protein export hsa03060
Cell Process Eukaryotic translation
Cell apoptosis
In-vitro Model 5637 Bladder carcinoma Homo sapiens CVCL_0126
RT-4 Bladder carcinoma Homo sapiens CVCL_0036
UM-UC-3 Bladder carcinoma Homo sapiens CVCL_1783
In-vivo Model Chose 4-week-old female BALB/c nude mice for tumor xenograft experiments, which randomly were divided into four groups (n = 5 per group). Bladder cancer cells (3 × 106) were subcutaneously injected into the right axilla of the nude mice.
Methyltransferase-like 3 (METTL3) [WRITER]
 Regulator Info 
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary Circ0008399 bound WTAP to promote formation of the WTAP/METTL3/METTL14 m6A methyltransferase complex, reduce cisplatin sensitivity in bladder cancer, implicating the potential therapeutic value of targeting this axis.
Target Regulation Up regulation
Responsed Disease Bladder cancer ICD-11: 2C94
 Disease Info 
Responsed Drug Cisplatin Approved
 Drug Info 
Pathway Response Protein export hsa03060
Cell Process Eukaryotic translation
Cell apoptosis
In-vitro Model 5637 Bladder carcinoma Homo sapiens CVCL_0126
RT-4 Bladder carcinoma Homo sapiens CVCL_0036
UM-UC-3 Bladder carcinoma Homo sapiens CVCL_1783
In-vivo Model Chose 4-week-old female BALB/c nude mice for tumor xenograft experiments, which randomly were divided into four groups (n = 5 per group). Bladder cancer cells (3 × 106) were subcutaneously injected into the right axilla of the nude mice.
Wilms tumor 1-associating protein (WTAP) [WRITER]
 Regulator Info 
In total 1 item(s) under this regulator
Experiment 1 Reporting the m6A Methylation Regulator of This Target Gene [1]
Response Summary Circ0008399 bound WTAP to promote formation of the WTAP/METTL3/METTL14 m6A methyltransferase complex, reduce cisplatin sensitivity in bladder cancer, implicating the potential therapeutic value of targeting this axis.
Target Regulation Up regulation
Responsed Disease Bladder cancer ICD-11: 2C94
 Disease Info 
Responsed Drug Cisplatin Approved
 Drug Info 
Pathway Response Protein export hsa03060
Cell Process Eukaryotic translation
Cell apoptosis
In-vitro Model 5637 Bladder carcinoma Homo sapiens CVCL_0126
RT-4 Bladder carcinoma Homo sapiens CVCL_0036
UM-UC-3 Bladder carcinoma Homo sapiens CVCL_1783
In-vivo Model Chose 4-week-old female BALB/c nude mice for tumor xenograft experiments, which randomly were divided into four groups (n = 5 per group). Bladder cancer cells (3 × 106) were subcutaneously injected into the right axilla of the nude mice.
Bladder cancer [ICD-11: 2C94]
 Disease Info 
In total 3 item(s) under this disease
Experiment 1 Reporting the m6A-centered Disease Response [1]
Response Summary Circ0008399 bound WTAP to promote formation of the WTAP/METTL3/METTL14 m6A methyltransferase complex, reduce cisplatin sensitivity in bladder cancer, implicating the potential therapeutic value of targeting this axis.
Responsed Disease Bladder cancer [ICD-11: 2C94]
Target Regulator Methyltransferase-like 14 (METTL14) WRITER
 Regulator Info 
Target Regulation Up regulation
Responsed Drug Cisplatin Approved
 Drug Info 
Pathway Response Protein export hsa03060
Cell Process Eukaryotic translation
Cell apoptosis
In-vitro Model 5637 Bladder carcinoma Homo sapiens CVCL_0126
RT-4 Bladder carcinoma Homo sapiens CVCL_0036
UM-UC-3 Bladder carcinoma Homo sapiens CVCL_1783
In-vivo Model Chose 4-week-old female BALB/c nude mice for tumor xenograft experiments, which randomly were divided into four groups (n = 5 per group). Bladder cancer cells (3 × 106) were subcutaneously injected into the right axilla of the nude mice.
Experiment 2 Reporting the m6A-centered Disease Response [1]
Response Summary Circ0008399 bound WTAP to promote formation of the WTAP/METTL3/METTL14 m6A methyltransferase complex, reduce cisplatin sensitivity in bladder cancer, implicating the potential therapeutic value of targeting this axis.
Responsed Disease Bladder cancer [ICD-11: 2C94]
Target Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
Target Regulation Up regulation
Responsed Drug Cisplatin Approved
 Drug Info 
Pathway Response Protein export hsa03060
Cell Process Eukaryotic translation
Cell apoptosis
In-vitro Model 5637 Bladder carcinoma Homo sapiens CVCL_0126
RT-4 Bladder carcinoma Homo sapiens CVCL_0036
UM-UC-3 Bladder carcinoma Homo sapiens CVCL_1783
In-vivo Model Chose 4-week-old female BALB/c nude mice for tumor xenograft experiments, which randomly were divided into four groups (n = 5 per group). Bladder cancer cells (3 × 106) were subcutaneously injected into the right axilla of the nude mice.
Experiment 3 Reporting the m6A-centered Disease Response [1]
Response Summary Circ0008399 bound WTAP to promote formation of the WTAP/METTL3/METTL14 m6A methyltransferase complex, reduce cisplatin sensitivity in bladder cancer, implicating the potential therapeutic value of targeting this axis.
Responsed Disease Bladder cancer [ICD-11: 2C94]
Target Regulator Wilms tumor 1-associating protein (WTAP) WRITER
 Regulator Info 
Target Regulation Up regulation
Responsed Drug Cisplatin Approved
 Drug Info 
Pathway Response Protein export hsa03060
Cell Process Eukaryotic translation
Cell apoptosis
In-vitro Model 5637 Bladder carcinoma Homo sapiens CVCL_0126
RT-4 Bladder carcinoma Homo sapiens CVCL_0036
UM-UC-3 Bladder carcinoma Homo sapiens CVCL_1783
In-vivo Model Chose 4-week-old female BALB/c nude mice for tumor xenograft experiments, which randomly were divided into four groups (n = 5 per group). Bladder cancer cells (3 × 106) were subcutaneously injected into the right axilla of the nude mice.
Cisplatin [Approved]
 Drug Info 
In total 3 item(s) under this drug
Experiment 1 Reporting the m6A-centered Drug Response [1]
Response Summary Circ0008399 bound WTAP to promote formation of the WTAP/METTL3/METTL14 m6A methyltransferase complex, reduce cisplatin sensitivity in bladder cancer, implicating the potential therapeutic value of targeting this axis.
Target Regulator Methyltransferase-like 14 (METTL14) WRITER
 Regulator Info 
Target Regulation Up regulation
Responsed Disease Bladder cancer ICD-11: 2C94
 Disease Info 
Pathway Response Protein export hsa03060
Cell Process Eukaryotic translation
Cell apoptosis
In-vitro Model 5637 Bladder carcinoma Homo sapiens CVCL_0126
RT-4 Bladder carcinoma Homo sapiens CVCL_0036
UM-UC-3 Bladder carcinoma Homo sapiens CVCL_1783
In-vivo Model Chose 4-week-old female BALB/c nude mice for tumor xenograft experiments, which randomly were divided into four groups (n = 5 per group). Bladder cancer cells (3 × 106) were subcutaneously injected into the right axilla of the nude mice.
Experiment 2 Reporting the m6A-centered Drug Response [1]
Response Summary Circ0008399 bound WTAP to promote formation of the WTAP/METTL3/METTL14 m6A methyltransferase complex, reduce cisplatin sensitivity in bladder cancer, implicating the potential therapeutic value of targeting this axis.
Target Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
Target Regulation Up regulation
Responsed Disease Bladder cancer ICD-11: 2C94
 Disease Info 
Pathway Response Protein export hsa03060
Cell Process Eukaryotic translation
Cell apoptosis
In-vitro Model 5637 Bladder carcinoma Homo sapiens CVCL_0126
RT-4 Bladder carcinoma Homo sapiens CVCL_0036
UM-UC-3 Bladder carcinoma Homo sapiens CVCL_1783
In-vivo Model Chose 4-week-old female BALB/c nude mice for tumor xenograft experiments, which randomly were divided into four groups (n = 5 per group). Bladder cancer cells (3 × 106) were subcutaneously injected into the right axilla of the nude mice.
Experiment 3 Reporting the m6A-centered Drug Response [1]
Response Summary Circ0008399 bound WTAP to promote formation of the WTAP/METTL3/METTL14 m6A methyltransferase complex, reduce cisplatin sensitivity in bladder cancer, implicating the potential therapeutic value of targeting this axis.
Target Regulator Wilms tumor 1-associating protein (WTAP) WRITER
 Regulator Info 
Target Regulation Up regulation
Responsed Disease Bladder cancer ICD-11: 2C94
 Disease Info 
Pathway Response Protein export hsa03060
Cell Process Eukaryotic translation
Cell apoptosis
In-vitro Model 5637 Bladder carcinoma Homo sapiens CVCL_0126
RT-4 Bladder carcinoma Homo sapiens CVCL_0036
UM-UC-3 Bladder carcinoma Homo sapiens CVCL_1783
In-vivo Model Chose 4-week-old female BALB/c nude mice for tumor xenograft experiments, which randomly were divided into four groups (n = 5 per group). Bladder cancer cells (3 × 106) were subcutaneously injected into the right axilla of the nude mice.
References
Ref 1 Circ0008399 Interaction with WTAP Promotes Assembly and Activity of the m(6)A Methyltransferase Complex and Promotes Cisplatin Resistance in Bladder Cancer. Cancer Res. 2021 Dec 15;81(24):6142-6156. doi: 10.1158/0008-5472.CAN-21-1518. Epub 2021 Oct 26.